Thomas Hansen
Chief Technology Officer Circio ASA
Seminars
Thursday 28th May 2026
Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
9:00 am
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning
Thursday 28th May 2026
circVec: A Circular RNA Vector–Driven Expression System for NextGeneration Cell and Gene Therapy
2:30 pm
- circVec, a novel gene expression platform developed by Circio, utilizes the high intra-cellular stability of circular RNA (up to 75 times longer half-life than mRNA) to achieve enhanced protein expression from viral and non-viral DNA vectors
- The low decay rate of circular RNA leads to high accumulation over time, particularly in specific tissues, such as heart, spleen, and eye, which enables safer and/or more effective gene and cell therapy in these areas
- Low accumulation of circRNA in hepatic tissue and overall lower stimulation of the UPR pathway compared to mRNA-based vectors suggest reduced tox and cellular stress upon systemic injection of circVec-based vectors
